Primary Vitamin D Target Genes Allow a Categorization of Possible Benefits of Vitamin D3 Supplementation
Open Access
- 29 July 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (7), e71042
- https://doi.org/10.1371/journal.pone.0071042
Abstract
Vitamin D deficiency has been associated with an increased risk of developing a number of diseases. Here we investigated samples from 71 pre-diabetic individuals of the VitDmet study, a 5-month high dose vitamin D3 intervention trial during Finnish winter, for their changes in serum 25-hydroxyvitamin D3 (25(OH)D3) concentrations and the expression of primary vitamin D target genes in peripheral blood mononuclear cells and adipose tissue. A negative correlation between serum concentrations of parathyroid hormone and 25(OH)D3 suggested an overall normal physiological vitamin D response among the participants. The genes CD14 and thrombomodulin (THBD) are up-regulated primary vitamin D targets and showed to be suitable gene expression markers for vitamin D signaling in both primary tissues. However, in a ranking of the samples concerning their expected response to vitamin D only the top half showed a positive correlation between the changes of CD14 or THBD mRNA and serum 25(OH)D3 concentrations. Interestingly, this categorization allows unmasking a negative correlation between changes in serum concentrations of 25(OH)D3 and the inflammation marker interleukin 6. We propose the genes CD14 and THBD as transcriptomic biomarkers, from which the effects of a vitamin D3 supplementation can be evaluated. These biomarkers allow the classification of subjects into those, who might benefit from a vitamin D3 supplementation, and others who do not.Keywords
This publication has 46 references indexed in Scilit:
- Plasma 25 hydroxyvitamin D level and blood gene expression profiles: a cross-sectional study of the Norwegian Women and Cancer Post-genome CohortEuropean Journal of Clinical Nutrition, 2013
- Chromatin acetylation at transcription start sites and vitamin D receptor binding regions relates to effects of 1α,25-dihydroxyvitamin D3 and histone deacetylase inhibitors on gene expressionNucleic Acids Research, 2012
- Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studiesThe Lancet, 2012
- Nuclear hormone 1α,25-dihydroxyvitamin D3 elicits a genome-wide shift in the locations of VDR chromatin occupancyNucleic Acids Research, 2011
- A ChIP-seq defined genome-wide map of vitamin D receptor binding: Associations with disease and evolutionGenome Research, 2010
- Common genetic determinants of vitamin D insufficiency: a genome-wide association studyThe Lancet, 2010
- Benefit–risk assessment of vitamin D supplementationOsteoporosis International, 2009
- Vitamin D Deficiency and Risk of Cardiovascular DiseaseCirculation, 2008
- IL6 genotypes and colon and rectal cancerCancer Causes & Control, 2007
- Vitamin D DeficiencyNew England Journal of Medicine, 2007